Description
What is BPC-157 + Thymosin-β4 Fragment (Oral Capsules)?
This oral capsule pairs the two most widely studied “healing” peptides in a gut‑stable encapsulation: BPC‑157 at 500 µg and the Thymosin β4 17‑aa active fragment (TB‑500) at 2.5 mg. BPC‑157 is the only peptide in this class with published evidence of oral bioactivity in rodents (gastric‑stable); TB‑500 oral bioavailability is less well characterized.
Mechanism of Action — Combined
- BPC‑157: Gastric‑stable partial sequence of a body‑protective protein; upregulates VEGF‑R2 and eNOS, accelerates angiogenesis, and has shown protective effects on gut barrier and tendon/ligament healing in rodent models.
- TB‑500: Actin sequestration and cell‑migration promotion; primarily studied after parenteral administration.
- Oral rationale: BPC‑157’s published oral activity makes it a reasonable candidate for capsule delivery; the TB‑500 fragment is included as an adjunct though its oral pharmacology is not well established.
Compound Properties
- Composition: BPC‑157 500 µg + Tβ4 17‑aa fragment 2.5 mg per capsule
- Form: Oral capsule
- Unit size: 60 capsules per bottle
- Source: Solid‑phase peptide synthesis; individual peptide ≥98% purity by HPLC prior to encapsulation
Research‑Reference Dosing
Published research‑reference ranges:
- Sikiric et al., Current Pharmaceutical Design (2010): oral BPC‑157 effective in rodent gut and musculoskeletal models.
- Chang et al., Tohoku Journal of Experimental Medicine (2011): oral BPC‑157 accelerated tendon‑fibroblast outgrowth ex vivo.
- No published human PK or efficacy data exist for this specific oral blend.
Research Findings
- Oral BPC‑157 demonstrates bioactivity in rodent GI, tendon, and muscle models (Sikiric, Chang)
- TB‑500 oral bioavailability is not well characterized; most published efficacy data involves parenteral dosing
- Combined oral use is a preclinical research protocol without dedicated published pharmacology
Known Side Effects Reported in Research/Trials
- Mild GI upset occasionally reported with capsule‑based peptide delivery
- No characteristic adverse event profile for the oral combination
- Theoretical pro‑angiogenic caution in occult neoplasia
- Long‑term human safety data unavailable
Storage & Handling
- Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
- After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
- Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.
Certificate of Analysis
A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.
Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.
